Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Must have received: BTK inhibitor — CLL/SLL

Subjects may also have slowly progressed on irreversible BTK inhibitors while on treatment with these agents.

Must have received: BCR antagonist — CLL/SLL

For CLL/SLL subjects who come off BCR antagonist treatment (BTK inhibitors, P13K inhibitors, etc.) allows washout for 2 days

Must have received: JAK2 antagonist — MF

For MF subjects who come off JAK2 antagonists, allow washout for 2 days

Must have received: proteasome inhibitor — MM

Relapsed or refractory multiple myeloma (MM) subjects who have received a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38

Must have received: immunomodulatory drug — MM

Relapsed or refractory multiple myeloma (MM) subjects who have received a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38

Must have received: anti-CD38 — MM

Relapsed or refractory multiple myeloma (MM) subjects who have received a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38

Must have received: tyrosine kinase inhibitor (bosutinib, dasatinib, imatinib, nilotinib, ponatinib) — ALL (B cell phenotype)

ALL subjects with B cell phenotype who have received at least two prior therapeutic regimens (such as multi-agent chemotherapy and/or tyrosine kinase inhibitors including bosutinib, dasatinib, imatinib, nilotinib or ponatinib) and failed

Must have received: CD19-based target therapy (blinatumomab) — ALL (B cell phenotype)

currently ineligible/intolerant for CD19-based target therapy (e.g. Blinatumomab)

Cannot have received: autologous/allogeneic hematopoietic stem cell transplantation

Exception: allowed if >60 days since transplant and off immunosuppressive therapy for at least 4 weeks

Subjects who have undergone autologous/allogeneic hematopoietic stem cell transplantation (HSCT) therapy within 60 days of the first dose of LP-118, or subjects on immunosuppressive therapy post-HSCT at the time of Screening

Cannot have received: CAR-T cell therapy

Exception: allowed if >28 days since CAR-T and no evidence of CRS or other adverse events

There is a 28-day washout period required for subjects who have had prior CAR-T treatment if there is no evidence of cytokine release syndrome (CRS) or other adverse events related to the CAR-T treatment

Cannot have received: any anti-neoplastic therapy

Exception: allowed if >14 days or 5 half-lives (whichever is shorter) since last therapy and recovered to ≤ Grade 2 AEs (excluding neuropathy)

Any anti-neoplastic therapy including chemotherapy, hormonal therapy, radiotherapy, biologic or immunotherapy, targeted small molecule agents, etc.

Cannot have received: investigational therapy

Exception: allowed if >14 days or 5 half-lives (whichever is shorter) since last therapy

Any investigational therapy

Cannot have received: live vaccines

Live vaccines